Feature|Articles|August 11, 2026

Everything You Need to Know About the AstraZeneca–Bristol Myers Squibb Merger Rumors

The AstraZeneca–BMS merger story explained: what was reported, what was denied, what regulators would scrutinize, and what it means for pharma.

Last week, reports emerged of a potential merger between AstraZeneca and Bristol Myers Squibb. While a senior source reportedly debunked these rumors days later, the news caused an uproar across the industry.

Related to this article

Pharmaceutical Executive daily
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.